GAITHERSBURG, Md., Oct. 29, 2012 (GLOBE NEWSWIRE) -- Sigma-Tau Pharmaceuticals, Inc. today announced the appointment of Jeff Hackman as its new Vice President of Commercial Operations. Mr. Hackman has joined the leadership team at Sigma-Tau Pharmaceuticals Inc.'s U.S. corporate headquarters, in Gaithersburg, Maryland.
Most recently, at Intercell AG, Mr. Hackman served as the Chief Executive Officer of the U.S. office and Global Senior Vice President, Commercial Operations, where he managed the group global marketing and sales function, focusing on the successful launch of the Company's first licensed product. Prior to this role, he held the position of Vice President, Global Marketing and Sales at Emergent Biosolutions, with responsibility to manage and build the company's global vaccine marketing and sales organization. Previous to this, as the Vice President, Marketing for MedImmune, Inc., he helped establish and build that company's marketing organization, including the successful launches of FluMist® and Synagis®. Mr. Hackman has also served as the Director of Marketing at Aventis Pasteur, Inc., and held various sales and marketing positions with American Cyanamid's Lederle Laboratories Pharmaceutical Division.
"Jeff's extensive and proven industry experience in global marketing and sales will prove to be invaluable as Sigma-Tau continues to pursue its growth goals and bring new and innovative rare disease drugs to market," said Dave Lemus, Chief Executive Officer of Sigma-Tau Pharmaceuticals, Inc. "We welcome Jeff to the Sigma-Tau team and look forward to utilizing his expertise going forward."
About Sigma-Tau Pharmaceuticals, Inc.
Sigma-Tau Pharmaceuticals, Inc. is a U.S. based, wholly owned subsidiary of the sigma-tau Group, and is dedicated to the global development and commercialization of medicines for patients with rare diseases. Sigma-Tau Pharmaceuticals, Inc. is based in Gaithersburg, Maryland. Since 1989, the company's products have been focused on kidney disease, certain genetic disorders and cancers. With more than 7,000 identified rare diseases that affect approximately 30 million patients in the U.S. alone, Sigma-Tau places its considerable scientific resources behind the development and commercialization of compounds that benefit the few. The company has a substantial development program focused on transplant, cancer, inherited genetic disorders, malaria, and other areas of unmet medical need. For more information about the company, visit www.sigmatau.com.
The Sigma-Tau Pharmaceuticals logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=14992